1,4-Dihydropyridine calcium channel ligands: Selectivity of action. The roles of pharmacokinetics, state-dependent interactions, channel isoforms, and other factors

Drug Development Research

Volumn 58, Issue 1, 2003, Pages 5-17

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

1,4 Dihydropyridine; Amiodipine; Calcium antagonists; Nifedipine; Nimodipine; Vascular selectivity

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 1,4 DIHYDROPYRIDINE DERIVATIVE; 2 [[2 (2 AMINOETHOXY)ETHOXY]METHYL] 4 (2,3 DICHLOROPHENYL) 1,4 DIHYDRO 6 METHYL 3,5 PYRIDINEDICARBOXYLIC ACID 3 ETHYL 5 METHYL ESTER; AMLODIPINE; ANGIOTENSIN; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CILNIDIPINE; DILTIAZEM; FELODIPINE; ISRADIPINE; LACIDIPINE; LERCENADIPINE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; SDZ 207180; UNCLASSIFIED DRUG; VERAPAMIL;

ANGINA PECTORIS; BINDING AFFINITY; BINDING SITE; BRAIN VASOSPASM; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CHANNEL GATING; CONFERENCE PAPER; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTROPHYSIOLOGY; GLOMERULUS FILTRATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DEPOLARIZATION; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MEMBRANE COMPONENT; MEMBRANE STEADY POTENTIAL; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 0037282547     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10124     Document Type: Conference Paper

References (77)

1. Alker D, Campbell S, Cross PE, Bueges RA, Carter AJ, Gaediner DG. 1990. Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationship for a series of basic and nonbasic derivatives of [(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonist. J Med Chem 33:585-591.
2. Angelico P, Guarneri L, Leonardi A, Testa R. 1999. Vascularselective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 51:709-714.
3. Armstrong CM, Hille B. 1998. Voltage-gated ion channels and electrical excitability. Neuron 20:371-380.
4. Arrowsmith JE, Campbell S, Cross PE, Stubbs JK, Burges RA, Gardiner DG, Blackburn KJ. 1986. Long-acting dihydropyridine calcium antagonists. 1.2-Alkoxymethyl derivatives incorporating basic substituents. J Med Chem 29:1696-1702.
5. Ashcroft FM. 2000. Ion channels and disease. San Diego: Academic Press.
6. 3HPN 200 110 binding to cell membranes and intact strips of portal vein smooth muscle: characterization and modulation by membrane potential and divalent cations. Br J Pharmacol 97:256-262.
7. Bassolini-Klimas D, Alper HE, Stouch TR. 1993. Solute diffusion in lipid bilayer membranes: anatomic level study by molecular dynamics simulation. Biochemistry 32:12624-126637.
8. Bean BP. 1984. Nitrendipine block of cardiac calcium channels: high affinity binding to the inactivated state. Proc Natl Acad Sci USA 81:6388-6392.
9. Bean BP, Sturek M, Puga A, Hermsmeyer K. 1986. Calcium channels in muscle cells isolated from rat mesenteric arteries: modulation by dihydropyridine drugs. Circ Res 59:229-235.
10. Bergsmann JB, Wheeeler DB, Tsien RW. 2000. Classification and function of voltage-gated calcium channels. In: Endo M, Kurachi Y, Mishina M, editors. Pharmacology of ionic channels. Handbook of experimental pharmacology, vol. 147. Berlin: Springer. p 55-85.
11. Catterall WA. 1995. Structure and function of voltage-gated ion channels. Annu Rev Biochem 64:493-531.
12. Chalmers J. 1999. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17:151-183.
13. Chester DW, Herbette LG, Mason RP, Joslyn AF, Triggle DJ, Koppel DG. 1987. Diffuison of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multilayers. Biophys J 52:1021-1030.
14. 2+ channel activator [Bay K 8644] and inhibitor [PN 200 110]. Proc Natl Acad Sci USA 83:1518-1522.
15. Epstein M, 1999. Role of a third-generation calcium antagonist in the management of hypertension. Drugs 57(Suppl 1):1-10.
16. Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, Schwartz A, Snutch TP, Tanabe T, Birnbaumer L, Tsien RW, Catteral WA. 2000. Nomenclature of voltage-gated calcium channels. Neuron 25:533-535.
17. Ferrante J, Luchowski EM, Rutledge A, Triggle DJ. 1989. Binding of a 1,4-dihydropyridine calcium channel activator, (-) S Bay K 8644, to cardiac preparations. Biochem Biophys Res Commun 158:149-154.
18. Fleckenstein A. 1977. Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Annu Rev Pharmacol 17:149-166.
19. Fleckenstein A. 1983a. Calcium antagonism in heart and smooth muscle. Experimental facts and therapeutic prospects. New York: John Wiley & Sons.
20. Fleckenstein A. 1983b. History of calcium antagonists. Circ Res 52(Suppl I):3-16.
21. 2+ channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 291:464-473.
22. Godfraind T, Salomone S, Dessy C, Verheist B, Dion R, Schoevaerts JC. 1992. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovas Pharmacol 20(Suppl 5):S34-S41.
23. Guarneri L, Angelico P, Ibba M, et al. 1996. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arz Forsch 46:15-24.
24. Hall ST, Harding SM, Evans GL, Pellegatti M, Rizzini P. 1991. Clinical pharmacology of lacidipine. J Cardiovasc Pharmacol 17(Suppl 4):S9-S13.
25. Heilbrunn LV. 1943. An outline of general physiology. Philadelphia: WB Saunders.
26. Herbette LG, Gavirhagi G, Tulenko T, Mason RP. 1993. Molecular interactions between lacidipine and biological membranes. J Hypertens 11:S13-S19.
27. Herbette LG, Mason PE, Gavirhagi G, Tulenko TN, Mason RP. 1994. The molecular basis for lacidipines unique pharmacokinetics: optimal hydrophobicity results in membrane interactions that may ficilitate the treatment of atherosclerosis. J Cardiovasc Pharmacol 23(Suppl 5):S16-S25.
28. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. 1998. Lercanidipine: short plasma half life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press 7 (Suppl 2):S10-S17.
29. Hockerman GH, Peterson BZ, Johnson BD, Catterall WA. 1997. Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol 37: 361-396.
30. Hofmann F, Klugbauer N. 2000. Structure of the voltage-dependent L-type calcium channel. In: Endo M, Kurachi Y, Mishina M, editors. Pharmacology of ionic channels. Handbook of experimental pharmacology, vol. 147. Heidelberg: Springer. p 87-117.
31. Hofmann F, Lacinova L, Klugbauer N. 1999. Voltage-dependent calcium channels from structure to function. Rev Biochem Physiol 139:33-88.
32. Hondeghem LM, Katzung BG. 1985. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel blocking drugs. Annu Rev Pharmacol Toxicol 24:387-423.
33. Hu H, Marban E. 1998. Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-3specific gating properties. Mol Pharmacol 53:902-907.
34. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, on Behalf of Members of. 1987. Transfer of nimodipine and another calcium antagonist across the regional blood-brain barrier and their regional distribution in vivo. In: Bergener, Reisberg, editors. The diagnosis and treatment of senile dementia. Berlin: Springer. p 308-321.
35. Kass RS. 1987. Voltage-dependent modulation of cardiac calcium channel current by optical isomers of Bay K 8644: implications for channel gating. Circ Res 61(Suppl 1):11-15.
36. Krippet-Drews P, Morel N, Godfraind T. 1992. Effect of nitric oxide on membrane potential and contraction of rat aorta. J Cardiovasc Pharmacol 20(Suppl 12):S72-S75.
37. Lacinova L, Klugbauer N, Hofmann F. 1999. Reconstruction of the 1,4-dihydropyridine site in a non-L-type calcium channel: the role of the IS6 segment. FEBS Lett 451:152-156.
38. 1C L-type calcium channel. Pflug Arch Eur J Physiol 440:50-60.
39. Lehmann-Horn F, Jurkat-Rott. 1999. Voltage-gated ion channels and hereditary disease. Physiol Rev 79:1317-1356.
40. Mason RP, Moring J, Herbette LG. 1989. A molecular model involving the membrane bilayer in the binding of lipid soluble drugs to their receptors in heart and brain. Nucl Med Biol 17: 13-33.
41. Mason RP, Rhodes DG, Herbette L. 1991. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 34:869-877.
42. McCarthy RT. 1989. Nimodipine block of L-type calcium channels in dorsal root ganglion cells. In: Traber J, Gispen W, editors. Nimodipine and central nervous system function: new vistas. Stuttgart: Schattauer. p 35-51.
43. McCarthy RT, Cohen CJ. 1989. Nimodipine block of calcium channels in vascular smooth muscle cell lines: exceptionally high affinity binding in A7r5 and A10 cell. J Gen Physiol 94:669-692.
44. McLellan KJ, Jarvis B. 2000. Lercanidipine: a review of its use in hypertension. Drugs 60:1123-1140.
45. Micheli D, Collodel A, Semeraro C, Gaviraghi G, Carpi C. 1990. Lacidipine, a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies. J Cardiovasc Pharmacol 16:666-677.
46. Morel N, Godfraind T. 1987. Prolonged depolarization increases the pharmacological effect of dihydropyridines and their binding affinity for calcium channels of vascular smooth muscle. J Pharmacol Exp Ther 243:711-715.
47. Morel N, Godfraind T. 1988. Selective modulation by membrane potential of the interaction of some calcium entry blockers with calcium channels in mesenteric artery. Br J Pharmacol 95: 252-258.
48. Morel N, Godfraind T. 1989. Pharmacological properties of voltage-dependent channels in functional microvessels from rat brain. Naunyn Schmid Arch Pharmacol 340:442-451.
49. Morel N, Godfraind T. 1991. Characterization in rat aorta of the binding sites responsible for blockade of noradrenaline-evoked calcium entry by nisoldipine. Br J Pharmacol 102:467-477.
50. Morel N, Godfraind T. 1994. Selective interaction of the calcium antagonist amlodipine with calcium channels in arteries of spontaneously hypertensive rats. J. Cardiovasc Pharmacol 24:524-533.
51. 1-subunits. Br J Pharmacol 125: 1005-1012.
52. Nelson MT, Worley JF. 1989. Dihydropyridine inhibition of single calcium channels and contraction in rabbit mesenteric artery depends on voltage. J Physiol 412:65-91.
53. Opie LH, Yusuf S, Kubler W. 2000. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog Cardiovase Dis 43:171-196.
54. Pasanisi F, Merdeith PA, Reid JL. 1985. The pharmacokinetics and pharmacodynamics of a new calcium antagonist nisoldipine in normotensive and hypertensive patients. Eur J Clin Pharmacol 29:21-24.
55. Putney JW (ed.). 2000. Calcium signaling. Boca Raton, FL: CRC Press.
56. 2+ channel inhibition by a new dihydropyridine derivative S11568 and its enantiomers S12967 and S12968. Eur J Pharmacol 190:85-96.
57. Reid JL, Meredith PA, Donnelly R, Elliott HL. 1988. Pharmacokinetics of calcium antagonists. J Cardiovasc Pharmacol 12(Suppl 7):S22-S26.
58. Ringer S. 1883. A further contribution regarding the influence of the different constitutents of the blood on the contraction of the heart. J Physiol 4:29-42.
59. Sanguinetti MC, Kass RS. 1984. Voltage-dependent block of calcium channel current in calf cardiac Purkinje fibers by dihydropyridine calcium channel antagonists. Circ Res 55:336-348.
60. Stopher DA, Bereford AP, Macrae PV, Humphrey MJ. 1988. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 12(Suppl 7):S55-S59.
61. Striessnig J, Grabner M, Mitterdorfer J, Hering S, Sinneger MJ, Glossmann H. 1998. Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol Sci 19:108-115.
62. 3H]nifedipine binding to intact vascular smooth muscle cells. Am J Phaysiol 254:C45-C52.
63. Sun JP, Triggle DJ. 1995. Calcium channel antagonists: cardiovascular selectivity of action. J Pharmacol Exp Ther 274:419-426.
64. Triggle DJ. 1972. Effects of calcium on excitable membranes and neurotransmitter action. Prog Surf Membr Sci 5:267-331.
65. Triggle DJ. 1989. Structure-function correlations of 1,4-dihydropyridine calcium channel antagonists and activators. In: Hondeghem LM, editor. Molecular and cellular mechanisms of antiarrhythmic agents. Mt. Kiscoe, NY: Futura.
66. Triggle DJ. 1990. Calcium antagonists. History and perspective. Stroke 21(Suppl IV):49-58.
67. Triggle DJ. 1991. Calcium channel drugs: structure-function relationships. J Cardiovasc Pharmacol 18:S1-S6.
68. Triggle DJ. 2002. Mechanisms of action of calcium channel antagonists. In: Epstein M, editor. Calcium antagonists in clinical medicine. Philadelphia: Hanley and Belfus.
69. Triggle DJ, Langs DA, Janis RA. 1991. Structure-function relationships of the 1,4-dihydropyridines. Med Res Rev 9:123-180.
70. 2+ channels in A7r5 cells by cilnidipine and its derivatives. Jpn J Pharmacol 85:260-270.
71. Van den Kerchoff W, Drewes LR. 1997. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Int Med 157:2413-2446.
72. Van den Maagdenburg AMJM, Frants RR. 2001. Voltage-gated calcium channels and their channelopathies. Pharm News 8:37-44
73. 2+ antagonists and activators in cultured neonatal rat ventricular myocytes. Mol Pharmacol 35:541-552.
74. Welling A, Kwan YK, Bosse E, Flockerzi V, Hofmann F, Kass RS. 1993. Subunit-dependent modulation of recombinant L-type calcium channels. Molecular basis for dihydropyridine tissue selectivity. Circ Res 73:974-980.
75. 2+ channels. Circ Res 81:526-533.
76. Yamada S, Sugimoto N, Uchida S, Deguchi Y, Kimura R. 1994. Pharmacokinetics of amlodipine and its occupancy of calcium antagonist receptors. J Cardiovasc Pharmacol 23:466-472.
77. Yatani A, Seidel CL, Allen J, Brown AM. 1987. Whole-cell and single-channel calcium currents of isolated smooth muscle cells from saphenous vein. Circ Res 60:523-533.